• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同疾病严重程度的 COVID-19 患者的实验室检测和宿主免疫。

The laboratory tests and host immunity of COVID-19 patients with different severity of illness.

机构信息

Department of Laboratory Medicine.

Department of Emergency Medicine, and.

出版信息

JCI Insight. 2020 May 21;5(10):137799. doi: 10.1172/jci.insight.137799.

DOI:10.1172/jci.insight.137799
PMID:32324595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7259533/
Abstract

BACKGROUNDThe coronavirus disease 2019 (COVID-19), infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak throughout the world. The host immunity of COVID-19 patients is unknown.METHODSThe routine laboratory tests and host immunity in COVID-19 patients with different severity of illness were compared after patient admission.RESULTSA total of 65 SARS-CoV-2-positive patients were classified as having mild (n = 30), severe (n = 20), and extremely severe (n = 15) illness. Many routine laboratory tests, such as ferritin, lactate dehydrogenase, and D-dimer, were increased in severe and extremely severe patients. The absolute numbers of CD4+ T cells, CD8+ T cells, and B cells were gradually decreased with increased severity of illness. The activation markers such as HLA-DR and CD45RO expressed on CD4+ and CD8+ T cells were increased in severe and extremely severe patients compared with mild patients. The costimulatory molecule CD28 had opposite results. The percentage of natural Tregs was decreased in extremely severe patients. The percentage of IFN-γ-producing CD8+ T cells was increased in both severe and extremely severe patients compared with mild patients. The percentage of IFN-γ-producing CD4+ T cells was increased in extremely severe patients. IL-2R, IL-6, and IL-10 were all increased in extremely severe patients. The activation of DC and B cells was decreased in extremely severe patients.CONCLUSIONThe number and function of T cells are inconsistent in COVID-19 patients. The hyperfunction of CD4+ and CD8+ T cells is associated with the pathogenesis of extremely severe SARS-CoV-2 infection.FUNDINGThis work was funded by the National Mega Project on Major Infectious Disease Prevention (2017ZX10103005-007) and the Fundamental Research Funds for the Central Universities (2019kfyRCPY098).

摘要

背景

由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)在全球范围内造成了严重爆发。COVID-19 患者的宿主免疫尚不清楚。

方法

对入院后不同严重程度 COVID-19 患者的常规实验室检查和宿主免疫进行比较。

结果

共 65 例 SARS-CoV-2 阳性患者分为轻症(n = 30)、重症(n = 20)和危重症(n = 15)。许多常规实验室检查,如铁蛋白、乳酸脱氢酶和 D-二聚体,在重症和危重症患者中升高。随着疾病严重程度的增加,CD4+T 细胞、CD8+T 细胞和 B 细胞的绝对数逐渐减少。与轻症患者相比,重症和危重症患者 CD4+和 CD8+T 细胞上的活化标志物 HLA-DR 和 CD45RO 表达增加。共刺激分子 CD28 则相反。危重症患者自然 Treg 的比例降低。与轻症患者相比,重症和危重症患者 IFN-γ 产生的 CD8+T 细胞的比例增加。与轻症患者相比,危重症患者 IFN-γ 产生的 CD4+T 细胞的比例增加。IL-2R、IL-6 和 IL-10 在危重症患者中均升高。DC 和 B 细胞的活化在危重症患者中减少。

结论

COVID-19 患者的 T 细胞数量和功能不一致。CD4+和 CD8+T 细胞的过度功能与严重 SARS-CoV-2 感染的发病机制有关。

资助

本研究得到国家重大传染病防治科技重大专项(2017ZX10103005-007)和中央高校基本科研业务费专项资金(2019kfyRCPY098)资助。

相似文献

1
The laboratory tests and host immunity of COVID-19 patients with different severity of illness.不同疾病严重程度的 COVID-19 患者的实验室检测和宿主免疫。
JCI Insight. 2020 May 21;5(10):137799. doi: 10.1172/jci.insight.137799.
2
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
3
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.严重 COVID-19 中免疫细胞细胞毒性受损依赖于白细胞介素 6。
J Clin Invest. 2020 Sep 1;130(9):4694-4703. doi: 10.1172/JCI138554.
4
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.SARS-CoV-2 感染免疫功能低下患者:体液免疫与细胞免疫。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000862.
5
Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.利用 IL-2R/淋巴细胞预测 COVID-19 患者的临床进展。
Clin Exp Immunol. 2020 Jul;201(1):76-84. doi: 10.1111/cei.13450. Epub 2020 May 15.
6
The Metabolic Changes and Immune Profiles in Patients With COVID-19.新型冠状病毒肺炎患者的代谢变化和免疫特征。
Front Immunol. 2020 Aug 28;11:2075. doi: 10.3389/fimmu.2020.02075. eCollection 2020.
7
Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease.分析 COVID-19 感染与急性疟疾中抑制性受体的表达:LAG-3 和 TIM-3 与 T 细胞激活和疾病过程相关。
Front Immunol. 2020 Aug 26;11:1870. doi: 10.3389/fimmu.2020.01870. eCollection 2020.
8
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.急性严重急性呼吸综合征冠状病毒 2 感染损害树突状细胞和 T 细胞应答。
Immunity. 2020 Oct 13;53(4):864-877.e5. doi: 10.1016/j.immuni.2020.07.026. Epub 2020 Aug 4.
9
Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病(COVID-19)住院儿科患者的临床和免疫特征。
JAMA Netw Open. 2020 Jun 1;3(6):e2010895. doi: 10.1001/jamanetworkopen.2020.10895.
10
Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.细胞毒性 T 细胞异常激活可能是 COVID-19 严重程度的一个决定因素。
Int J Infect Dis. 2020 Aug;97:313-321. doi: 10.1016/j.ijid.2020.05.106. Epub 2020 May 31.

引用本文的文献

1
Critical biomarkers in the battle against COVID-19: unveiling thrombotic risks and predictive indicators in Syrian hospitals.抗击新冠疫情中的关键生物标志物:揭示叙利亚医院的血栓形成风险和预测指标
Ann Med Surg (Lond). 2025 Mar 20;87(8):4803-4810. doi: 10.1097/MS9.0000000000003168. eCollection 2025 Aug.
2
COVID-19 coagulopathy and antiphospholipid syndrome.新型冠状病毒肺炎凝血病与抗磷脂综合征
Rev Colomb Reumatol. 2022 Jun;29:S25-S34. doi: 10.1016/j.rcreu.2021.02.013. Epub 2021 Aug 27.
3
Aging-associated changes in immunological parameters: Implications for COVID-19 immune response in the elderly.免疫参数的衰老相关变化:对老年人COVID-19免疫反应的影响。
Physiol Rep. 2025 May;13(10):e70364. doi: 10.14814/phy2.70364.
4
Susceptibility from the immunological perspective of COVID-19-associated pulmonary aspergillosis: A literature review.从免疫学角度看新型冠状病毒肺炎相关肺曲霉病的易感性:文献综述
Medicine (Baltimore). 2025 May 9;104(19):e42363. doi: 10.1097/MD.0000000000042363.
5
Deep insight into cytokine storm: from pathogenesis to treatment.深入洞察细胞因子风暴:从发病机制到治疗。
Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.
6
Heterogeneity and longitudinal transcriptomic characteristics of Tregs in COVID-19 patients.新冠患者中调节性T细胞的异质性和纵向转录组特征
Front Immunol. 2025 Mar 6;16:1548173. doi: 10.3389/fimmu.2025.1548173. eCollection 2025.
7
TIM3 in COVID-19; A potential hallmark?新冠病毒肺炎中的T细胞免疫球蛋白黏蛋白-3;一个潜在的标志?
Heliyon. 2024 Nov 13;10(23):e40386. doi: 10.1016/j.heliyon.2024.e40386. eCollection 2024 Dec 15.
8
The Value of Common Laboratory Markers in Predicting the Severity of COVID-19 Patients.常见实验室指标在预测新型冠状病毒肺炎患者病情严重程度中的价值
Infect Drug Resist. 2024 Nov 13;17:5037-5047. doi: 10.2147/IDR.S478798. eCollection 2024.
9
assessment of CAR macrophages activity against SARS-CoV-2 infection.评估嵌合抗原受体巨噬细胞对严重急性呼吸综合征冠状病毒2感染的活性。
Heliyon. 2024 Oct 23;10(21):e39689. doi: 10.1016/j.heliyon.2024.e39689. eCollection 2024 Nov 15.
10
Immunopathological markers and cell types linked to COVID-19 symptom manifestation.与 COVID-19 症状表现相关的免疫病理标志物和细胞类型。
BMC Infect Dis. 2024 Nov 4;24(1):1237. doi: 10.1186/s12879-024-10139-z.

本文引用的文献

1
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China.中国新型冠状病毒(2019-nCoV)的基因组组成和分化。
Cell Host Microbe. 2020 Mar 11;27(3):325-328. doi: 10.1016/j.chom.2020.02.001. Epub 2020 Feb 7.
2
Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak.2019 年至 2020 年中国新型冠状病毒(2019-nCoV)基本繁殖数的初步估计:疫情早期的基于数据的分析。
Int J Infect Dis. 2020 Mar;92:214-217. doi: 10.1016/j.ijid.2020.01.050. Epub 2020 Jan 30.
3
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征:描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
4
CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia.2019新型冠状病毒(2019-nCoV)肺炎的CT影像
Radiology. 2020 Apr;295(1):18. doi: 10.1148/radiol.2020200236. Epub 2020 Jan 31.
5
Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.德国一名无症状接触者传播2019新型冠状病毒感染
N Engl J Med. 2020 Mar 5;382(10):970-971. doi: 10.1056/NEJMc2001468. Epub 2020 Jan 30.
6
The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm.新型冠状病毒(2019 - nCoV)感染:抗击疫情面临的挑战
Eur J Clin Invest. 2020 Mar;50(3):e13209. doi: 10.1111/eci.13209. Epub 2020 Feb 5.
7
Drug treatment options for the 2019-new coronavirus (2019-nCoV).针对 2019 新型冠状病毒(2019-nCoV)的药物治疗选择。
Biosci Trends. 2020 Mar 16;14(1):69-71. doi: 10.5582/bst.2020.01020. Epub 2020 Jan 28.
8
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.新型冠状病毒受体识别:基于 SARS 冠状病毒长达十年结构研究的分析。
J Virol. 2020 Mar 17;94(7). doi: 10.1128/JVI.00127-20.
9
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.新型冠状病毒感染肺炎在中国武汉的早期传播动力学。
N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
10
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.实时 RT-PCR 检测 2019 新型冠状病毒(2019-nCoV)
Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000045.